Clinical trials
Completed Hypertension trials in Mexico
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 5 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 53 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takeda | 8 |
| Boehringer Ingelheim | 7 |
| Sanofi | 5 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 3 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| Coordinación de Investigación en Salud, Mexico | 2 |
| Instituto Mexicano del Seguro Social | 2 |
| Instituto Nacional de Cardiologia Ignacio Chavez | 2 |
| Mexican National Institute of Public Health | 2 |
| Anahuac University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 53 |
| Cardiovascular Diseases | 9 |
| Essential Hypertension | 6 |
| Diabetes Mellitus | 5 |
| Metabolic Syndrome | 5 |
| Obesity | 5 |
| Stroke | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Hyperlipidemias | 3 |
| Overweight | 3 |
Trials
Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.